Doximity (DOCS) Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Doximity in the last year. There are currently 3 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DOCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DOCS, but not buy additional shares or sell existing shares.
View DOCS analyst ratings or view top-rated stocks.

10 brokerages have issued 12-month target prices for Doximity's stock. Their DOCS share price forecasts range from $29.00 to $49.00. On average, they predict the company's share price to reach $37.00 in the next twelve months. This suggests a possible upside of 12.0% from the stock's current price.
View analysts price targets for DOCS or view top-rated stocks among Wall Street analysts.

Doximity's stock was trading at $33.56 on January 1st, 2023. Since then, DOCS shares have decreased by 1.6% and is now trading at $33.03.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our DOCS earnings forecast.

Doximity, Inc. (NASDAQ:DOCS) released its quarterly earnings data on Tuesday, May, 16th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.02. The business had revenue of $110.97 million for the quarter, compared to the consensus estimate of $110.11 million. Doximity had a trailing twelve-month return on equity of 12.74% and a net margin of 26.92%.

ETFs with the largest weight of Doximity (NASDAQ:DOCS) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Jacob Forward ETF (JFWD), Janus Henderson Small Cap Growth Alpha ETF (JSML), Fidelity Digital Health ETF (FDHT), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Harbor Corporate Culture Leaders ETF (HAPY).Renaissance IPO ETF (IPO).

Doximity issued an update on its first quarter 2024 earnings guidance on Friday, May, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $106.50 million-$107.50 million, compared to the consensus revenue estimate of $112.09 million.

(DOCS) raised $501 million in an initial public offering on Thursday, June 24th 2021. The company issued 23,300,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan Securities served as the underwriters for the IPO and Piper Sandler, William Blair, Canaccord and Raymond James were co-managers.

Doximity trades on the NASDAQ under the ticker symbol "DOCS."

Doximity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Clearbridge Investments LLC (3.50%), BlackRock Inc. (2.82%), FMR LLC (2.71%), Baillie Gifford & Co. (2.27%), Price T Rowe Associates Inc. MD (1.22%) and Credit Suisse AG (1.07%). Insiders that own company stock include Anna Bryson, Gilbert H Kliman, Interwest Partners X Lp, Joseph B Kleine, Kevin Spain, Kira Scherer Wampler, Paul W Jorgensen and Timothy S Cabral.
View institutional ownership trends.

Shares of DOCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DOCS stock can currently be purchased for approximately $33.03.

Doximity (NASDAQ:DOCS) has a market capitalization of $6.43 billion and generates $419.05 million in revenue each year. The company earns $112.82 million in net income (profit) each year or $0.52 on an earnings per share basis.

The company employs 850 workers across the globe.

The official website for the company is www.doximity.com. The company can be reached via phone at 650-549-4330 or via email at ir@doximity.com.